The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended adding sinus bradycardia to the product label for remdesivir as an adverse reaction of "unknown frequency."As part of its review, the committee examined all the available data on "rare" reported cases of bradycardia in patients, who re...

Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with me...

In a paper on the interim findings on the four drugs, WHO's Solidarity trial researchers in 30 countries return a clear negative. The multi-country Solidarity trial anchored by the World Health Organization (WHO) has concluded that none of the four repurposed drugs that it examined — remdesivir, hydroxychloroquine (HCQ),...

Remdesivir The broad-spectrum antiviral agent remdesivir is a nucleotide analog prodrug. On May 1, 2020, The FDA has granted an emergency use authorization (EUA) for remdesivir to treat hospitalized adults and children with suspected or laboratory-confirmed SARS CoV-2 infection and severe COVID-19 disease.   MANDATORY REQUIREMENTS FOR R...